AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04618354 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: This clinical study is a retrospective study, and no interventions have been implemented for patients.
Study NCT03467828 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analyzing
Description: Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
Study NCT02670512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehome Monitoring
Study NCT02976766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gypenosides
Description: Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
Study NCT02976766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo three times a day for 10 days.
Study NCT03191084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose THC Marijuana
Description: Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
Study NCT02165163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
Study NCT01628900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: care management arm N°1 vs arm N°2
Description: 7 days for mono-antibiotherapy at hospital
Study NCT02872155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hydratation
Description: 500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
Study NCT03191084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose THC Marijuana
Description: Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
Study NCT03191084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Marijuana
Description: Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
Study NCT02872155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate endovenous hydratation
Description: Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
Study NCT02872155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline endovenous hydratation
Description: If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
Study NCT00399477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline mesylate
Description: Azilect®
Study NCT00399477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate plus Mirapex
Description: Mirapex, Azilect®
Study NCT03213080 — intervention group
Intervention type: DEVICE
Intervention: Targeted Lung Denervation (TLD)
Description: Targeted Lung Denervation (TLD) procedure.
Study NCT01628900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care management
Description: Hospital vs home
Study NCT02838732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)
Study NCT00399477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate with Levodopa
Description: Azilect®, Levodopa
Study NCT00399477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate with Requip
Description: Azilect®, Requip
Study NCT02543346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetirizine
Description: Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
Study NCT02543346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
Study NCT04083638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IFAB
Description: Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
Study NCT01697072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00358722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg
Study NCT00648271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tablets 25 mg
Description: 2x50mg, single dose fed
Study NCT00648271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor® Tablets 50 mg
Description: 1x50mg, single dose fed
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is an anthracycline cytotoxic agent.
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is an anthracycline cytotoxic agent.
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Study NCT03045029 — intervention group
Intervention type: DRUG
Intervention: Oral treprostinil
Description: Sustained-release oral tablets for TID administration
Study NCT00788684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV infusion once weekly for four doses
Study NCT00788684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ABT-263: oral solution or tablets, once daily dosing until disease progression
Study NCT01358708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTEOL® 340 mg
Description: LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
Study NCT01358708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
Study NCT03526796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
Study NCT03162354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool
Description: The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture.
Study NCT02821117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management.
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is an oral fluoropyrimidine.
Study NCT01697072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an oral fluoropyrimidine.
Study NCT02124655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Study NCT02124655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Study NCT02124655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile water
Study NCT03410576 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid artery stenting
Description: Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.
Study NCT03410576 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
Study NCT00105547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-7869
Description: oral 800 mg BID
Study NCT00105547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPC-7869
Description: Oral BID dosing
Study NCT02288403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Study NCT02288403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous training
Study NCT04628143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Administered intravenously as a continuous infusion
Study NCT01498900 — intervention group
Intervention type: DRUG
Intervention: repaglinide
Description: Prescription according to the product labelling at the physicians' discretion
Study NCT04383561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and root planing (SRP), in four clinical visits
Study NCT04383561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.
Study NCT04383561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.
Study NCT00731354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction-assisted Lipoplasty
Description: Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
Study NCT00731354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VASER-assisted lipoplasty
Description: VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
Study NCT03809975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Community Program
Description: Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 \< BMI \<32.5; Psychology: PEG > 4 or PHQ-4 > 5 or PAM level \< 3
Study NCT03809975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current model of care
Description: No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
Study NCT01307865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid
Description: Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
Study NCT03061279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixation by Acutrak headless screw
Description: The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
Study NCT03061279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation by headed screws, plates, and or wires
Description: DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
Study NCT03548324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC
Description: Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
Study NCT01228162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: effect of muscle relaxation on muscle trauma, control group without relaxation
Description: effect of muscle relaxation on muscle trauma, control group without relaxation
Study NCT01852448 — intervention group
Intervention type: GENETIC
Intervention: Blood or Saliva Sample Collection
Description: A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
Study NCT01228162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: effect of muscle relaxation on muscle trauma, control group without relaxation
Description: effect of muscle relaxation on muscle trauma, control group without relaxation
Study NCT02529020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthguard
Description: Condition of wearing mouthguard
Study NCT02529020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No mouthguard
Description: Condition without mouthguard
Study NCT00707148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Study NCT00707148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Study NCT04632264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery
Description: The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
Study NCT04632264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Initiation of standard postpartum oxytocin immediately following placenta delivery
Description: Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
Study NCT04632264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Saline placebo will be initiated post placenta delivery (within 15 seconds).
Study NCT04632264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline Placebo
Description: Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
Study NCT02201368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin (SpezialölÒ 107®)
Description: * Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months
Study NCT02201368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin (SpezialölÒ 107®)
Description: * Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months
Study NCT02201368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT (Medium-Chain Triglycerides)
Description: * Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months
Study NCT02201368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT (Medium-Chain Triglycerides)
Description: * Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months
Study NCT00707148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
Study NCT00707148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
Study NCT04727905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: energy drink
Description: The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
Study NCT04727905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: energy drink
Description: The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
Study NCT03548324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
Study NCT03744806 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab Injection
Study NCT02845908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Study NCT02820935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Study NCT01115244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 5%
Description: ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.